PEG-MGF
A PEGylated splice variant of IGF-1 that activates muscle satellite cells and promotes muscle repair, with an extended half-life compared to natural MGF.
Also known as: PEGylated Mechano Growth Factor, PEG-MGF IGF-1Ec, PEGylated IGF-1Ec
Regulatory Status
Classification date: 2024-06-01
Compounding: Not currently available for compounding
Evidence Summary
Key Studies
How It Works
PEG-MGF is a synthetic PEGylated form of mechano growth factor, the Ec splice variant of IGF-1 produced locally in muscle tissue after mechanical stress. Natural MGF has a half-life of minutes; PEGylation extends this to hours. It activates muscle satellite (stem) cells, promoting their proliferation and fusion with existing muscle fibers for repair and hypertrophy. Unlike systemic IGF-1, MGF acts locally at the site of muscle damage and does not significantly raise circulating IGF-1 levels, potentially reducing systemic side effects.
Common Applications
Safety & Considerations
Limited human safety data. Potential for injection-site pain and swelling. As an IGF-1 variant, theoretical concerns about promoting growth of occult tumors exist. PEGylation may trigger immune responses in susceptible individuals. Not studied in controlled human clinical trials. Currently not legal for compounding in the US.
Regulatory classifications can change rapidly. The information shown here was last verified on 2024-06-01. Always confirm current legal status with a licensed provider or the FDA before making treatment decisions.